PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.35%
Revenue growth under 50% of META's 11.36%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
4.43%
Gross profit growth under 50% of META's 12.06%. Michael Burry would be concerned about a severe competitive disadvantage.
-2.42%
Negative EBIT growth while META is at 14.61%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-2.42%
Negative operating income growth while META is at 14.61%. Joel Greenblatt would press for urgent turnaround measures.
1.22%
Net income growth under 50% of META's 24.62%. Michael Burry would suspect the firm is falling well behind a key competitor.
16.00%
EPS growth at 50-75% of META's 23.08%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
16.00%
Diluted EPS growth at 50-75% of META's 24.00%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
0.42%
Share count expansion well above META's 0.45%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.41%
Diluted share count expanding well above META's 0.46%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-14.00%
Negative OCF growth while META is at 16.60%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-18.70%
Negative FCF growth while META is at 6.09%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
848.96%
10Y revenue/share CAGR above 1.5x META's 307.00%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
138.08%
5Y revenue/share CAGR under 50% of META's 307.00%. Michael Burry would suspect a significant competitive gap or product weakness.
26.56%
3Y revenue/share CAGR under 50% of META's 203.16%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
644.98%
10Y OCF/share CAGR above 1.5x META's 234.68%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
93.34%
Below 50% of META's 234.68%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
43.36%
3Y OCF/share CAGR under 50% of META's 645.29%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
737.27%
Net income/share CAGR above 1.5x META's 238.60% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
70.56%
Below 50% of META's 238.60%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
74.74%
Below 50% of META's 1383.66%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
960.33%
Equity/share CAGR of 960.33% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
149.42%
Equity/share CAGR of 149.42% while META is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
63.28%
Below 50% of META's 148.39%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.16%
AR growth is negative/stable vs. META's 10.74%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
68.09%
Inventory growth of 68.09% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
3.94%
Asset growth at 50-75% of META's 5.30%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
3.55%
75-90% of META's 4.51%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
-0.04%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
15.81%
R&D growth drastically higher vs. META's 8.63%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
4.82%
SG&A declining or stable vs. META's 12.89%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.